{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:28:39Z","timestamp":1787678919678,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["IM101-735"],"award-info":[{"award-number":["IM101-735"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.semarthrit.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T11:18:46Z","timestamp":1623064726000},"page":"685-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting"],"prefix":"10.1016","volume":"51","author":[{"given":"Seulggie","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeongzu","family":"Ghang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seogsong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10055","key":"10.1016\/j.semarthrit.2021.06.002_bib0001","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.06.002_bib0003","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"10.1016\/j.semarthrit.2021.06.002_bib0004","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.06.002_bib0006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","article-title":"Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis","volume":"20","author":"Chastek","year":"2017","journal-title":"J Med Econ"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.06.002_bib0007","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","volume":"34","author":"Wei","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.06.002_bib0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0009","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","article-title":"Ten years with biologics: to whom do data on effectiveness and safety apply?","volume":"50","author":"Simard","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.06.002_bib0010","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0011","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13075-019-1917-8","article-title":"Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata(R) clinical database and registry","volume":"21","author":"Choquette","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2021.06.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez120","article-title":"Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register","author":"Frisell","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0013","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","article-title":"Drug retention of 7 biologics and tofacitinib in biologics-naive and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study","volume":"22","author":"Ebina","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.06.002_bib0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40744-020-00201-y","article-title":"Real-world persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic","volume":"7","author":"Best","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3904\/kjim.2019.411","article-title":"The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus","volume":"35","author":"Park","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.06.002_bib0016","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00296-015-3353-7","article-title":"Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-alpha treatment and comparison to other guidelines","volume":"35","author":"Hur","year":"2015","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.06.002_bib0017","first-page":"799","article-title":"Data resource profile: the national health information database of the national health insurance service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.semarthrit.2021.06.002_bib0018","doi-asserted-by":"crossref","DOI":"10.4178\/epih\/e2014008","article-title":"A guide for the utilization of health insurance review and assessment service national patient samples","volume":"36","author":"Kim","year":"2014","journal-title":"Epidemiol Health"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0019","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/rheumatology\/kem308","article-title":"The epidemiology of total knee replacement in South Korea: national registry data","volume":"47","author":"Kim","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.06.002_bib0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4082\/kjfm.20.0062","article-title":"Conducting and reporting a clinical research using korean healthcare claims database","volume":"41","author":"Kim","year":"2020","journal-title":"Korean J Fam Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.06.002_bib0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3904\/kjim.2016.374","article-title":"Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data","volume":"34","author":"Jung","year":"2019","journal-title":"Korean J Intern Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.06.002_bib0022","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","article-title":"Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database","volume":"33","author":"Cho","year":"2013","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.06.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.06.002_bib0024","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.06.002_bib0025","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.06.002_bib0026","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","article-title":"Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies","volume":"53","author":"Favalli","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"57 Suppl 7","key":"10.1016\/j.semarthrit.2021.06.002_bib0027","doi-asserted-by":"crossref","first-page":"vii42","DOI":"10.1093\/rheumatology\/key195","article-title":"Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian expert consensus","volume":"57","author":"Todoerti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2021.06.002_bib0028","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/PPA.S47453","article-title":"Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis","volume":"7","author":"Martinez-Santana","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.06.002_bib0029","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10067-017-3584-y","article-title":"Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry","volume":"36","author":"Park","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.06.002_bib0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12891-017-1684-0","article-title":"Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis","volume":"18","author":"Wilke","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.06.002_bib0031","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3111\/13696998.2014.893241","article-title":"Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting","volume":"17","author":"Meissner","year":"2014","journal-title":"J Med Econ"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.06.002_bib0032","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/acr.21663","article-title":"Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British society for rheumatology biologics register","volume":"64","author":"Soliman","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.06.002_bib0033","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamainternmed.2018.2310","article-title":"Association of obesity or weight change with coronary heart disease among young adults in South Korea","volume":"178","author":"Choi","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"17","key":"10.1016\/j.semarthrit.2021.06.002_bib0034","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1001\/jama.2018.16501","article-title":"Association of blood pressure classification in korean young adults according to the 2017 American college of cardiology\/American heart association guidelines with subsequent cardiovascular disease events","volume":"320","author":"Son","year":"2018","journal-title":"JAMA"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:05:41Z","timestamp":1758733541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0049017221001128"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.06.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}